Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
St. Jude Children's Research Hospital
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
68High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07616154CT.gov Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease | — | Not Yet Recruiting | — | — | — |
NCT06872333CT.gov Allo HSCT for High Risk Hemoglobinopathies | — | Recruiting | — | — | — |
NCT06145282CT.gov Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function | — | Active Not Recruiting | — | — | — |
NCT06078696CT.gov Siplizumab for Sickle Cell Disease Transplant | — | Terminated | — | — | — |
NCT05736419CT.gov A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) | — | Recruiting | — | — | — |
NCT04776850CT.gov Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies | — | Withdrawn | — | — | — |
NCT04362293CT.gov Reduced Intensity Transplantation for Severe Sickle Cell Disease | — | Suspended | — | — | — |
NCT02757885CT.gov Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow | — | Completed | — | — | — |
NCT03249831CT.gov A Blood Stem Cell Transplant for Sickle Cell Disease | — | Active Not Recruiting | — | — | — |
NCT03653338CT.gov T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias | — | Recruiting | — | — | — |
Show 21 more trialsShow fewer
NCT03263559CT.gov Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507) | — | Completed | — | — | — |
NCT03609840CT.gov Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients | — | Completed | — | — | — |
NCT03077542CT.gov Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease | — | Active Not Recruiting | — | — | — |
NCT03121001CT.gov Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease | — | Recruiting | — | — | — |
NCT02867800CT.gov Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease | — | Completed | — | — | — |
NCT02678143CT.gov Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease | — | Terminated | — | — | — |
NCT03609814CT.gov Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT) | — | Completed | — | — | — |
NCT02105766CT.gov Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure | — | Active Not Recruiting | — | — | — |
NCT02013375CT.gov SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD | — | Terminated | — | — | — |
NCT01850108CT.gov Non-Myeloablative Conditioning and Bone Marrow Transplantation | — | Unknown | — | — | — |
NCT01461837CT.gov Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease | — | Active Not Recruiting | — | — | — |
NCT01049854CT.gov CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant | — | Completed | — | — | — |
NCT01279616CT.gov A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease | — | Terminated | — | — | — |
NCT00977691CT.gov Haploidentical PBMC Transplant for Severe Congenital Anemias | — | Active Not Recruiting | — | — | — |
NCT00489281CT.gov Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders | — | Terminated | — | — | — |
NCT00578344CT.gov Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP | — | Terminated | — | — | — |
NCT00152113CT.gov Haploidentical Stem Cell Transplant for Patients With Sickle Cell Disease and Prior Stroke or Abnormal Transcranial Ultrasound | — | Completed | — | — | — |
NCT00176852CT.gov Stem Cell Transplant for Hemoglobinopathy | — | Completed | — | — | — |
NCT00040469CT.gov Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies | — | Terminated | — | — | — |
NCT00029380CT.gov Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia | — | Completed | — | — | — |
NCT00186810CT.gov Stem Cell Transplantation With Identical Donors for Patients With Sickle Cell Disease | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sickle Cell Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | St. Jude Children's Research Hospital | P2/3 | BB · 67 |
| Glutamine | Ain Shams University | P4 | BBB |
| Hydroxyurea | St. Jude Children's Research Hospital | P4 | BB |
| Crizanlizumab | Novartis Pharmaceuticals | P4 | BB |
| Magnesium Metallicum | Medical College of Wisconsin | P3 | BB |
| Nivestim | St. Jude Children's Research Hospital | P4 | BB |
| Nepenthe | Oman Medical Speciality Board | P4 | BB |
| Fentanyl | University College Dublin | P4 | BB |
| ARG | Tanta University | P3 | BB |
+42 more in the Sickle Cell Disease cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Sickle Cell Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-sickle-cell-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →